SkyePharma Completes Enrollment for Flutiform Efficacy Trials

UK drugmaker SkyePharma has enrolled all patients in three double-blind efficacy trials for Flutiform, an asthma treatment.

The three trials involve approximately 1,400 patients and will provide data for the new drug application in the U.S. and a European marketing authorization application.  

SkyePharma said it anticipates completing the trials in April 2008.